Letrozole
A to Z Drug Facts
Letrozole |
(let-ROW-zahl) |
Femara |
Tablets |
2.5 mg. |
Class: Nonsteroidal aromatase inhibitor |
Action A nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. Elimination half-life is approximately 2 days. It is weakly protein bound. Renal excretion is the major pathway of letrozole clearance.
Indications Advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy; first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic cancer.
Contraindications Standard considerations.
Breast Cancer Adults: PO 2.5 mg once daily (tablets).
Contraceptives, oral May alter the efficacy of oral contraceptives.
Tamoxifen Plasma concentrations of letrozole may be decreased.
Lab Test Interferences None well documented.
CARDIOVASCULAR: Chest pain; hypertension; peripheral edema. CNS: Decreased appetite; fatigue; headache; insomnia; somnolence; dizziness; asthenia; weakness. DERMATOLOGIC: Rash; pruritis; alopecia. GI: Nausea and vomiting; constipation; diarrhea; abdominal pain; anorexia; dyspepsia. GU: Sexual inactivity; atrophy of the female reproductive organs; breast pain. METABOLIC: Hot flashes; weight gain; hypercholesterolemia; weight loss. RESPIRATORY: Dyspnea; coughing. OTHER: Viral infections; musculoskeletal pain; arthralgia; flu-like symptoms.
Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Hepatic function impairment: Use caution in patients with severe hepatic dysfunction.
PATIENT CARE CONSIDERATIONS |
|
Books@Ovid
Copyright © 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts